Mar, N.; Zakharia, Y.; Falcon, A.; Morales-Barrera, R.; Mellado, B.; Duran, I.; Oh, D.-Y.; Williamson, S.K.; Gajate, P.; Arkenau, H.-T.;
et al. Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers 2023, 15, 2978.
https://doi.org/10.3390/cancers15112978
AMA Style
Mar N, Zakharia Y, Falcon A, Morales-Barrera R, Mellado B, Duran I, Oh D-Y, Williamson SK, Gajate P, Arkenau H-T,
et al. Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers. 2023; 15(11):2978.
https://doi.org/10.3390/cancers15112978
Chicago/Turabian Style
Mar, Nataliya, Yousef Zakharia, Alejandro Falcon, Rafael Morales-Barrera, Begona Mellado, Ignacio Duran, Do-Youn Oh, Stephen K. Williamson, Pablo Gajate, Hendrik-Tobias Arkenau,
and et al. 2023. "Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma" Cancers 15, no. 11: 2978.
https://doi.org/10.3390/cancers15112978
APA Style
Mar, N., Zakharia, Y., Falcon, A., Morales-Barrera, R., Mellado, B., Duran, I., Oh, D.-Y., Williamson, S. K., Gajate, P., Arkenau, H.-T., Jones, R. J., Teo, M. Y., Turan, T., McLaughlin, R. T., Peltier, H. M., Chong, E., Atluri, H., Dean, J. P., & Castellano, D.
(2023). Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers, 15(11), 2978.
https://doi.org/10.3390/cancers15112978